Various compounds targeted at the NCp7 zinc fingers have been developed, but only one, HPH116 (cGMP micronized azodicarbonamide), has entered clinical trials so far.
2010
NEW PATENT
2008
HPH116
Food Drug Interaction
is achieved.
H-Phar foreseens a pilot
therapeutic vaccine clinical trial
in Q4 2010
